Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Jarrard

Showing results (81-90 of 132) with videos related to

Pageof 14
Sort By:
BJU International|November 15, 2008
Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-GuérinJason R Gee, David F Jarrard, Reginald C Bruskewitz, et al.
Clinical Epigenetics|June 7, 2020
CTCF loss mediates unique DNA hypermethylation landscapes in human cancersNathan A Damaschke, Joseph Gawdzik, Mele Avilla, et al.
Journal of Proteome Research|July 5, 2018
HyPR-MS for Multiplexed Discovery of MALAT1, NEAT1, and NORAD lncRNA Protein InteractomesMichele Spiniello, Rachel A Knoener, Maisie I Steinbrink, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 24, 2006
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1Mohammad Saleem, Vaqar Mustafa Adhami, Weixiong Zhong, et al.
The Journal of Urology|April 25, 2023
Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023)William Lowrance, Robert Dreicer, David F Jarrard, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2007
Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomyGordon W Wong, Kerrin L Palazzi-Churas, David F Jarrard, et al.
European Urology Oncology|April 30, 2024
Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED)Daniel Sentana-Lledo, Xiangying Chu, David F Jarrard, et al.
Cancer Research|August 15, 2008
Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostateVivian X Fu, Joseph R Dobosy, Joshua A Desotelle, et al.
Plos One|February 25, 2017
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapyMichael L Blute, Nathan Damaschke, Jennifer Wagner, et al.
BJU International|November 22, 2015
Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancerMichael L Blute, Kristin Zorn, Matthew Grimes, et al.
Pageof 14

Showing results (81-90 of 132) with videos related to

Sort By:
Pageof 14
BJU International|November 15, 2008
Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-GuérinJason R Gee, David F Jarrard, Reginald C Bruskewitz, et al.
Clinical Epigenetics|June 7, 2020
CTCF loss mediates unique DNA hypermethylation landscapes in human cancersNathan A Damaschke, Joseph Gawdzik, Mele Avilla, et al.
Journal of Proteome Research|July 5, 2018
HyPR-MS for Multiplexed Discovery of MALAT1, NEAT1, and NORAD lncRNA Protein InteractomesMichele Spiniello, Rachel A Knoener, Maisie I Steinbrink, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 24, 2006
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1Mohammad Saleem, Vaqar Mustafa Adhami, Weixiong Zhong, et al.
The Journal of Urology|April 25, 2023
Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023)William Lowrance, Robert Dreicer, David F Jarrard, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2007
Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomyGordon W Wong, Kerrin L Palazzi-Churas, David F Jarrard, et al.
European Urology Oncology|April 30, 2024
Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED)Daniel Sentana-Lledo, Xiangying Chu, David F Jarrard, et al.
Cancer Research|August 15, 2008
Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostateVivian X Fu, Joseph R Dobosy, Joshua A Desotelle, et al.
Plos One|February 25, 2017
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapyMichael L Blute, Nathan Damaschke, Jennifer Wagner, et al.
BJU International|November 22, 2015
Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancerMichael L Blute, Kristin Zorn, Matthew Grimes, et al.
Pageof 14